通过靶向肿瘤相关巨噬细胞的嵌合受体工程化溶瘤病毒重振内源性抗肿瘤免疫
Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy.
Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肝细胞癌(HCC)因其广泛发病率和高度死亡率仍然是全球健康挑战。HCC由于其独特的生理结构而具有特定的免疫耐受功能,这限制了化疗、放疗和分子靶向治疗的疗效。近年来,新的免疫方法,包括过继细胞治疗、肿瘤疫苗和溶瘤病毒治疗,已显示出巨大潜力。由于免疫治疗的疗效主要取决于肿瘤免疫微环境的空间异质性,因此有必要阐明肝癌免疫环境组成之间的串扰,从中可以选择潜在的治疗靶点,以提供更合适的个体化治疗方案。全面分析了HCC微环境中免疫细胞空间异质性在疾病进展中的作用以及免疫治疗对改善HCC治疗和预后的影响,为后续肝癌的临床治疗提供了新的启示。
Hepatocellular carcinoma (HCC) remains a global health challenge owing to its widespread incidence and high mortality. HCC has a specific immune tolerance function because of its unique physiological structure, which limits the efficacy of chemotherapy, radiotherapy, and molecular targeting. In recent years, new immune approaches, including adoptive cell therapy, tumor vaccines, and oncolytic virus therapy, have shown great potential.
As the efficacy of immunotherapy mainly depends on the spatial heterogeneity of the tumor immune microenvironment, it is necessary to elucidate the crosstalk between the composition of the liver cancer immune environment, from which potential therapeutic targets can be selected to provide more appropriate individualized treatment programs.
The role of spatial heterogeneity of immune cells in the microenvironment of HCC in the progression and influence of immunotherapy on improving the treatment and prognosis of HCC were comprehensively analyzed, providing new inspiration for the subsequent clinical treatment of liver cancer.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。